Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MYO7B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MYO7B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/MYO7B_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00516482 | Colorectum | MSS | vesicle localization | 53/3467 | 177/18723 | 1.47e-04 | 2.16e-03 | 53 |
GO:00995152 | Colorectum | MSS | actin filament-based transport | 11/3467 | 21/18723 | 4.85e-04 | 5.65e-03 | 11 |
GO:00300502 | Colorectum | MSS | vesicle transport along actin filament | 10/3467 | 19/18723 | 8.39e-04 | 8.68e-03 | 10 |
GO:00307052 | Colorectum | MSS | cytoskeleton-dependent intracellular transport | 52/3467 | 195/18723 | 3.07e-03 | 2.34e-02 | 52 |
GO:00070154 | Colorectum | FAP | actin filament organization | 125/2622 | 442/18723 | 1.97e-15 | 3.03e-12 | 125 |
GO:00300483 | Colorectum | FAP | actin filament-based movement | 44/2622 | 127/18723 | 3.48e-09 | 5.93e-07 | 44 |
GO:00516563 | Colorectum | FAP | establishment of organelle localization | 97/2622 | 390/18723 | 5.91e-09 | 9.48e-07 | 97 |
GO:00516503 | Colorectum | FAP | establishment of vesicle localization | 48/2622 | 161/18723 | 1.56e-07 | 9.64e-06 | 48 |
GO:00516483 | Colorectum | FAP | vesicle localization | 50/2622 | 177/18723 | 5.41e-07 | 2.72e-05 | 50 |
GO:00995153 | Colorectum | FAP | actin filament-based transport | 12/2622 | 21/18723 | 4.76e-06 | 1.57e-04 | 12 |
GO:00300503 | Colorectum | FAP | vesicle transport along actin filament | 11/2622 | 19/18723 | 1.01e-05 | 2.93e-04 | 11 |
GO:00307053 | Colorectum | FAP | cytoskeleton-dependent intracellular transport | 47/2622 | 195/18723 | 1.06e-04 | 1.76e-03 | 47 |
GO:0099518 | Colorectum | FAP | vesicle cytoskeletal trafficking | 22/2622 | 73/18723 | 2.88e-04 | 3.77e-03 | 22 |
GO:00070155 | Colorectum | CRC | actin filament organization | 104/2078 | 442/18723 | 4.75e-14 | 7.12e-11 | 104 |
GO:00300484 | Colorectum | CRC | actin filament-based movement | 42/2078 | 127/18723 | 2.96e-11 | 1.97e-08 | 42 |
GO:00995154 | Colorectum | CRC | actin filament-based transport | 12/2078 | 21/18723 | 3.80e-07 | 3.12e-05 | 12 |
GO:00516564 | Colorectum | CRC | establishment of organelle localization | 76/2078 | 390/18723 | 6.53e-07 | 4.50e-05 | 76 |
GO:00300504 | Colorectum | CRC | vesicle transport along actin filament | 11/2078 | 19/18723 | 9.91e-07 | 6.18e-05 | 11 |
GO:00307054 | Colorectum | CRC | cytoskeleton-dependent intracellular transport | 45/2078 | 195/18723 | 1.29e-06 | 7.21e-05 | 45 |
GO:00516504 | Colorectum | CRC | establishment of vesicle localization | 39/2078 | 161/18723 | 1.82e-06 | 9.07e-05 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MYO7B | SNV | Missense_Mutation | rs371739405 | c.2725N>A | p.Val909Ile | p.V909I | Q6PIF6 | protein_coding | tolerated(0.74) | benign(0) | TCGA-A2-A0T0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
MYO7B | SNV | Missense_Mutation | novel | c.3913N>G | p.Leu1305Val | p.L1305V | Q6PIF6 | protein_coding | deleterious(0) | probably_damaging(0.931) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
MYO7B | SNV | Missense_Mutation | | c.4493N>T | p.Gly1498Val | p.G1498V | Q6PIF6 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-A8-A075-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | epirubicin | CR |
MYO7B | SNV | Missense_Mutation | novel | c.4180N>C | p.Glu1394Gln | p.E1394Q | Q6PIF6 | protein_coding | deleterious(0.05) | benign(0.011) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
MYO7B | SNV | Missense_Mutation | | c.1667N>T | p.Gly556Val | p.G556V | Q6PIF6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A1AO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MYO7B | SNV | Missense_Mutation | rs576789048 | c.38N>G | p.Glu13Gly | p.E13G | Q6PIF6 | protein_coding | deleterious(0.01) | benign(0.05) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MYO7B | SNV | Missense_Mutation | rs576789048 | c.38N>G | p.Glu13Gly | p.E13G | Q6PIF6 | protein_coding | deleterious(0.01) | benign(0.05) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MYO7B | SNV | Missense_Mutation | rs576789048 | c.38N>G | p.Glu13Gly | p.E13G | Q6PIF6 | protein_coding | deleterious(0.01) | benign(0.05) | TCGA-BH-A0HU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
MYO7B | SNV | Missense_Mutation | | c.1791N>C | p.Leu597Phe | p.L597F | Q6PIF6 | protein_coding | tolerated(0.57) | possibly_damaging(0.588) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD |
MYO7B | SNV | Missense_Mutation | | c.4426N>A | p.Glu1476Lys | p.E1476K | Q6PIF6 | protein_coding | tolerated(0.07) | benign(0.169) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |